|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||48.11 - 48.49|
|52 Week Range||44.76 - 54.26|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||17.84|
|Forward Dividend & Yield||1.93 (4.00%)|
|Ex-Dividend Date||May 03, 2021|
|1y Target Est||63.40|
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents, and adults Results provide insight into the clinical and real-world experience of Dupixent on key disease measures including itch, disease severity, sleep and anxietyDupixent pr
Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
In the past five years, British firms have faced Brexit, a crash in the value of the pound and long coronavirus lockdowns – but that has not hindered returns for some businesses.